Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis

Pharmaceutical Research Department, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

Reocclusion of infarct-related coronary arteries within 2 weeks of thrombolytic therapy varies from 5% to 45% and neither clinical nor angiographic variables have been proved to be predictive of reocclusion. The goal of the present study was to evaluate whether aspirin could prevent coronary reocclusion and recurrent ischemia after thrombolysis. For this purpose, a meta-analysis including 32 studies was performed. Although the studies showed very similar demographic data, the reocclusion rate assessed by angiography in 419 patients treated with aspirin was 11% compared with 25% in 513 patients without aspirin therapy (p less than 0.001). Recurrent ischemic events were present in 25% of 2,977 patients treated with aspirin and 41% of 721 patients treated without aspirin (p less than 0.001). The effect of aspirin was similar in trials with either streptokinase or recombinant tissue-type plasminogen activator (rt-PA). Thus, aspirin in the presence of heparin might prevent coronary reocclusion after thrombolysis.

This article has been cited by other articles:

				J. Hopkins and M. Limacher The Role of Aspirin in Cardiovascular Disease Prevention in Women American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 123 - 134. [Abstract] [PDF]

				T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]

				The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., January 1, 2003; 24(1): 28 - 66. [Full Text] [PDF]

				M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]

				J. Lopez-Sendon Coronary reperfusion in the clinical setting: antithrombotic support to thrombolysis in the coronary care unit Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C55 - C61. [Abstract] [PDF]

				E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]

				I. B A Menown and A A J. Adgey Improving reperfusion after myocardial infarction BMJ, December 11, 1999; 319(7224): 1513 - 1515. [Full Text]

				C. P. Cannon Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402. [Abstract] [Full Text] [PDF]

				J. K. French, T. A. Hyde, H. Patel, D. J. Amos, S. C. McLaughlin, B. J. Webber, and H. D. White Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks J. Am. Coll. Cardiol., July 1, 1999; 34(1): 62 - 69. [Abstract] [Full Text] [PDF]

				G. Frostfeldt, G. Ahlberg, G. Gustafsson, G. Helmius, B. Lindahl, A. Nygren, A. Siegbahn, E. Swahn, P. Venge, and L. Wallentin Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction--a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) J. Am. Coll. Cardiol., March 1, 1999; 33(3): 627 - 633. [Abstract] [Full Text] [PDF]

				L. D. Ramunno, T. A. Dodds, and N. D. Traven Cooperative Cardiovascular Project (CCP) Quality Improvement in Maine, New Hampshire, and Vermont Eval Health Prof, December 1, 1998; 21(4): 442 - 460. [Abstract] [PDF]

				E. M. Ohman, N. S. Kleiman, G. Gacioch, S. J. Worley, F. I. Navetta, J. D. Talley, H. V. Anderson, S. G. Ellis, M. D. Cohen, D. Spriggs, et al. Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial Circulation, February 18, 1997; 95(4): 846 - 854. [Abstract] [Full Text]

				C. V. Jackson, J. Satterwhite, and E. Roberts Preclinical and Clinical Pharmacology of Efegatran (LY294468) : A Novel Antithrombin for the Treatment of Acute Coronary Syndromes Clinical and Applied Thrombosis/Hemostasis, October 1, 1996; 2(4): 258 - 267. [Abstract] [PDF]

				E. M. Antman Hirudin in Acute Myocardial Infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial Circulation, September 1, 1996; 94(5): 911 - 921. [Abstract] [Full Text]

				M. J. Eisenberg and E. J. Topol Prehospital Administration of Aspirin in Patients With Unstable Angina and Acute Myocardial Infarction Arch Intern Med, July 22, 1996; 156(14): 1506 - 1510. [Abstract] [PDF]

				F. M. Sheridan, P. G. Cole, and D. Ramage Leukocyte Adhesion to the Coronary Microvasculature During Ischemia and Reperfusion in an In Vivo Canine Model Circulation, May 15, 1996; 93(10): 1784 - 1787. [Abstract] [Full Text]

				S.-K. Yao, S. Akhtar, T. Scott-Burden, J. C. Ober, P. Golino, L. M. Buja, W. Casscells, and J. T. Willerson Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis Circulation, August 15, 1995; 92(4): 1005 - 1010. [Abstract] [Full Text]

				F. Leya, J. Fareed, and J. Walenga Acute Myocardial Infarction: Diagnosis and Management Clinical and Applied Thrombosis/Hemostasis, March 1, 1995; 1(2): 160 - 165. [Abstract] [PDF]

				J. S. Mruk, P. Zoldhelyi, M. W.I. Webster, M. Heras, D. E. Grill, D. R. Holmes Jr, V. Fuster, and J. H. Chesebro Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus? : Effects of Recombinant Hirudin, Heparin, or Aspirin Circulation, February 15, 1995; 93(4): 792 - 799. [Abstract] [Full Text]

				H. V. Anderson and J. T. Willerson Thrombolysis in Acute Myocardial Infarction N. Engl. J. Med., September 2, 1993; 329(10): 703 - 709. [Full Text]

				C. L. Grines, K. F. Browne, J. Marco, D. Rothbaum, G. W. Stone, J. O'Keefe, P. Overlie, B. Donohue, N. Chelliah, G. C. Timmis, et al. A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction N. Engl. J. Med., March 11, 1993; 328(10): 673 - 679. [Abstract] [Full Text]